Patient Derived Xenograft/PDX Model Market Report: Trends, Forecast and Competitive Analysis
Get it in 2 to 4 weeks by ordering today
The future of the patient derived xenograft/PDX model market looks promising with opportunities in the pre-clinical drug development and biomarker analysis.. The global patient derived xenograft/PDX models market is expected to grow with a CAGR of 15%-18% from 2020 to 2025. The major drivers for this market are rising prevelance of chronic diseases and increasing demand of personalized medicine.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global patient derived xenograft/PDX models market report, please download the report brochure.
In this market, mice models is the largest type of xenograft/PDX model, whereas pharmaceutical and biotechnology companies is the largest end user. Growth in various segments of the xenograft/PDX model market are given below:
The study includes trends and forecast for the global patient derived xenograft/PDX model market by type, tumor type, application, end user, and region as follows:
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
Lucintel forecasts that the mice model segment will remain the largest segment over the forecast period due to large number of mice which enhances surgical manipulation in models for cancer treatment.
Within this market pharmaceutical and biotechnology companies will remain the largest segment by end users over the forecast period due to increasing expenditure on research and development by companies for drug development.
North America will remain the largest region over the forecast period due to growth in biomedical research, rising preclinical activities by clinical research organisations and pharmaceutical companies, and growing stem cell research in the region.
Features of the Global Patient Derived Xenograft/PDX Model Market
Q.1 What are some of the most promising potential, high-growth opportunities for the global patient derived xenograft/PDX model market by type (mice model and rats model), tumor type (gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, other tumor models), applications (pre-clinical drug development and basic cancer research and biomarker analysis), end user (pharmaceutical and biotechnology companies, contract research organizations, and academic & research institutions) and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global patient derived xenograft/PDX models market?
Q.5 What are the business risks and threats to the global patient derived xenograft/PDX models market?
Q.6 What are the emerging trends in this patient derived xenograft/PDX models market and the reasons behind them?
Q.7 What are some changing demands of customers in this patient derived xenograft/PDX models market?
Q.8 What are the new developments in this patient derived xenograft/PDX models market? Which companies are leading these developments?
Q.9 Who are the major players in this patient derived xenograft/PDX models market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this patient derived xenograft/PDX models market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global patient derived xenograft/PDX models market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Type (Mice Model and Rats Model), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models, and Other Tumor Models), Applications (Pre-Clinical Drug Development And Basic Cancer Research and Biomarker Analysis), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutions)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
The future of the patient derived xenograft/PDX model market looks promising with opportunities in the pre-clinical drug development and biomarker analysis.. The global patient derived xenograft/PDX models market is expected to grow with a CAGR of 15%-18% from 2020 to 2025. The major drivers for this market are rising prevelance of chronic diseases and increasing demand of personalized medicine.
A total of XX figures / charts and XX tables are provided in this more than 150-page report to help in your business decisions. Sample figures with some insights are shown below. To learn the scope, benefits, companies researched, and other details of the global patient derived xenograft/PDX models market report, please download the report brochure.
In this market, mice models is the largest type of xenograft/PDX model, whereas pharmaceutical and biotechnology companies is the largest end user. Growth in various segments of the xenograft/PDX model market are given below:
The study includes trends and forecast for the global patient derived xenograft/PDX model market by type, tumor type, application, end user, and region as follows:
By Type [Value ($ Million) shipment analysis for 2014 – 2025]:
- Mice Model
- Rats Model
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Hematological Tumor Models
- Other Tumor Models
- Pre-clinical Drug Development and Basic Cancer Research
- Biomarker Analysis
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
- Academic and Research Institutions
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Spain
- German
- France
- Asia Pacific
- China
- India
- Japan
- The Rest of the World
- Brazil
Lucintel forecasts that the mice model segment will remain the largest segment over the forecast period due to large number of mice which enhances surgical manipulation in models for cancer treatment.
Within this market pharmaceutical and biotechnology companies will remain the largest segment by end users over the forecast period due to increasing expenditure on research and development by companies for drug development.
North America will remain the largest region over the forecast period due to growth in biomedical research, rising preclinical activities by clinical research organisations and pharmaceutical companies, and growing stem cell research in the region.
Features of the Global Patient Derived Xenograft/PDX Model Market
- Market Size Estimates: Global patient derived xenograft/PDX model market size estimation in terms of value ($M) shipment.
- Trend and Forecast Analysis: Market trends (2014-2019) and forecast (2020-2025) by various segments.
- Segmentation Analysis: Global patient derived xenograft/PDX model market size by various segments, such as type, tumor type, application, and end user in terms of value.
- Regional Analysis: Global patient derived xenograft/PDX model market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different type, tumor type, application, end user, and region for the global patient derived xenograft/PDX models market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the global patient derived xenograft/PDX models market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
Q.1 What are some of the most promising potential, high-growth opportunities for the global patient derived xenograft/PDX model market by type (mice model and rats model), tumor type (gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, other tumor models), applications (pre-clinical drug development and basic cancer research and biomarker analysis), end user (pharmaceutical and biotechnology companies, contract research organizations, and academic & research institutions) and region (North America, Europe, Asia Pacific, and Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3 Which region will grow at a faster pace and why?
Q.4 What are the key factors affecting market dynamics? What are the drivers and challenges of the global patient derived xenograft/PDX models market?
Q.5 What are the business risks and threats to the global patient derived xenograft/PDX models market?
Q.6 What are the emerging trends in this patient derived xenograft/PDX models market and the reasons behind them?
Q.7 What are some changing demands of customers in this patient derived xenograft/PDX models market?
Q.8 What are the new developments in this patient derived xenograft/PDX models market? Which companies are leading these developments?
Q.9 Who are the major players in this patient derived xenograft/PDX models market? What strategic initiatives are being implemented by key players for business growth?
Q.10 What are some of the competitive products and processes in this patient derived xenograft/PDX models market, and how big of a threat do they pose for loss of market share via material or product substitution?
Q.11 What M&A activities did take place in the last five years in the global patient derived xenograft/PDX models market?
Report Scope
Key Features Description
Base Year for Estimation 2019
Trend Period
(Actual Estimates) 2014-2019
Forecast Period 2020-2025
Pages More than 150
Market Representation / Units Revenue in US $ Million
Report Coverage Market Trends & Forecasts, Competitor Analysis, New Product Development, Company Expansion, Merger, Acquisitions & Joint Venture, and Company Profiling
Market Segments Type (Mice Model and Rats Model), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Respiratory Tumor Models, Urological Tumor Models, Hematological Tumor Models, and Other Tumor Models), Applications (Pre-Clinical Drug Development And Basic Cancer Research and Biomarker Analysis), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic & Research Institutions)
Regional Scope North America (USA, Mexico, and Canada), Europe (United Kingdom, Spain, Germany, and France), Asia (China, India, and Japan), and ROW (Brazil)
Customization 10% Customization without Any Additional Cost
1. EXECUTIVE SUMMARY
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Patient Derived Xenograft/PDX Models Market Trends and Forecast
3.3: Global Patient Derived Xenograft/PDX Models Market by Type
3.3.1: Mice Model
3.3.2: Rats Model
3.4: Global Patient Derived Xenograft/PDX Models Market by Tumor Type
3.4.1: Gastrointestinal Tumor Models
3.4.2: Gynecological Tumor Models
3.4.3: Respiratory Tumor Models
3.4.4: Urological Tumor Models
3.4.5: Hematological Tumor Models
3.4.6: Other Tumor Models
3.5: Global Patient Derived Xenograft/PDX Models Market by Application
3.5.1: Pre-clinical Drug Development and Basic Cancer Research
3.5.2: Biomarker Analysis
3.6: Global Patient Derived Xenograft/PDX Models Market by End User
3.6.1: Pharmaceutical and Biotechnology Companies
3.6.2: Contract Research Organizations
3.6.3: Academic and Research Institutions
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Patient Derived Xenograft/PDX Models Market by Region
4.2: North American Patient Derived Xenograft/PDX Models Market
4.2.1: Market by Type: Mice Model and Rats Model
4.2.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.2.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.2.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.2.5: The United States Patient Derived Xenograft/PDX Models Market
4.2.6: The Canadian Patient Derived Xenograft/PDX Models Market
4.2.7: The Mexican Patient Derived Xenograft/PDX Models Market
4.3: European Patient Derived Xenograft/PDX Models Market
4.3.1: Market by Type: Mice Model and Rats Model
4.3.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.3.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.3.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.3.5: The United Kingdom Patient Derived Xenograft/PDX Models Market
4.3.6: The Spanish Patient Derived Xenograft/PDX Models Market
4.3.7: The German Patient Derived Xenograft/PDX Models Market
4.3.8: The French Patient Derived Xenograft/PDX Models Market
4.4: APAC Patient Derived Xenograft/PDX Models Market
4.4.1: Market by Type: Mice Model and Rats Model
4.4.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.4.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.4.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.4.5: The Chinese Patient Derived Xenograft/PDX Models Market
4.4.6: The Indian Patient Derived Xenograft/PDX Models Market
4.4.7: The Japanese Patient Derived Xenograft/PDX Models Market
4.5: ROW Patient Derived Xenograft/PDX Models Market
4.5.1: Market by Type: Mice Model and Rats Model
4.5.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.5.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.5.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.5.5: Brazilian Patient Derived Xenograft/PDX Models Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Type
7.1.2: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Tumor Type
7.1.3: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Application
7.1.4: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by End User
7.1.5: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Region
7.2: Emerging Trends in the Global Patient Derived Xenograft/PDX Models Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Patient Derived Xenograft/PDX Models Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Patient Derived Xenograft/PDX Models Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Crown Bioscience Inc.
8.2: WuXi AppTec
8.3: Champions Oncology, Inc.
8.4: The Jackson Laboratory.
8.5: ONCODESIGN
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
2. MARKET BACKGROUND AND CLASSIFICATIONS
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. MARKET TRENDS AND FORECAST ANALYSIS FROM 2014 T 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Patient Derived Xenograft/PDX Models Market Trends and Forecast
3.3: Global Patient Derived Xenograft/PDX Models Market by Type
3.3.1: Mice Model
3.3.2: Rats Model
3.4: Global Patient Derived Xenograft/PDX Models Market by Tumor Type
3.4.1: Gastrointestinal Tumor Models
3.4.2: Gynecological Tumor Models
3.4.3: Respiratory Tumor Models
3.4.4: Urological Tumor Models
3.4.5: Hematological Tumor Models
3.4.6: Other Tumor Models
3.5: Global Patient Derived Xenograft/PDX Models Market by Application
3.5.1: Pre-clinical Drug Development and Basic Cancer Research
3.5.2: Biomarker Analysis
3.6: Global Patient Derived Xenograft/PDX Models Market by End User
3.6.1: Pharmaceutical and Biotechnology Companies
3.6.2: Contract Research Organizations
3.6.3: Academic and Research Institutions
4. MARKET TRENDS AND FORECAST ANALYSIS BY REGION
4.1: Global Patient Derived Xenograft/PDX Models Market by Region
4.2: North American Patient Derived Xenograft/PDX Models Market
4.2.1: Market by Type: Mice Model and Rats Model
4.2.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.2.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.2.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.2.5: The United States Patient Derived Xenograft/PDX Models Market
4.2.6: The Canadian Patient Derived Xenograft/PDX Models Market
4.2.7: The Mexican Patient Derived Xenograft/PDX Models Market
4.3: European Patient Derived Xenograft/PDX Models Market
4.3.1: Market by Type: Mice Model and Rats Model
4.3.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.3.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.3.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.3.5: The United Kingdom Patient Derived Xenograft/PDX Models Market
4.3.6: The Spanish Patient Derived Xenograft/PDX Models Market
4.3.7: The German Patient Derived Xenograft/PDX Models Market
4.3.8: The French Patient Derived Xenograft/PDX Models Market
4.4: APAC Patient Derived Xenograft/PDX Models Market
4.4.1: Market by Type: Mice Model and Rats Model
4.4.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.4.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.4.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.4.5: The Chinese Patient Derived Xenograft/PDX Models Market
4.4.6: The Indian Patient Derived Xenograft/PDX Models Market
4.4.7: The Japanese Patient Derived Xenograft/PDX Models Market
4.5: ROW Patient Derived Xenograft/PDX Models Market
4.5.1: Market by Type: Mice Model and Rats Model
4.5.2: Market by Tumor Type: Gastrointestinal, Gynecological, Respiratory, Urological, Hemtological, and Other Timor Models
4.5.3: Market by Application: Pre-clinical Drug Development and Basic Cancer Research and Biomarket Analysis
4.5.4: Market by End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, and Academic and Research Institutions
4.5.5: Brazilian Patient Derived Xenograft/PDX Models Market
5. COMPETITOR ANALYSIS
5.1: Market Share Analysis
5.2: Product Portfoli Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. COST STRUCTURE ANALYSIS
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. GROWTH OPPORTUNITIES AND STRATEGIC ANALYSIS
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Type
7.1.2: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Tumor Type
7.1.3: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Application
7.1.4: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by End User
7.1.5: Growth Opportunities for the Global Patient Derived Xenograft/PDX Models Market by Region
7.2: Emerging Trends in the Global Patient Derived Xenograft/PDX Models Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Patient Derived Xenograft/PDX Models Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Patient Derived Xenograft/PDX Models Market
7.3.4: Certification and Licensing
8. COMPANY PROFILES OF LEADING PLAYERS
8.1: Crown Bioscience Inc.
8.2: WuXi AppTec
8.3: Champions Oncology, Inc.
8.4: The Jackson Laboratory.
8.5: ONCODESIGN
8.6: Company
8.7: Company
8.8: Company
8.9: Company
8.10: Company
